Praxis Precision Medicines stopped its Phase 2/3 EMBOLD study early after an interim analysis showed significant efficacy of relutrigine, a sodium-channel modulator for developmental and epileptic encephalopathies. The data triggered an early efficacy stop and sent Praxis shares sharply higher. Company disclosures and follow-up briefings indicated consistent seizure reduction across disease severity and age groups, positioning relutrigine for accelerated approval discussions with the FDA. Praxis plans to use the dataset as the backbone for regulatory meetings and potential filing strategies. Investors and rival developers will watch subsequent regulatory feedback and confirmatory trial design, as early stops for efficacy can compress development timelines but also raise questions about long-term effects and broader patient populations.